Saturday, May 14, 2005
OncoLink coverage of the Annual Meeting of the American Society of Clinical Oncology, May 13-17, 2005, in Orlando, FL. OncoLink reporters provide in-depth, up-to-the-minute coverage of sessions and presentations.
A Randomized Phase III Trial Comparing Bexarotene/Carboplatin/Paclitaxel vs. Carboplatin/Paclitaxel in Chemotherapy-Naive Patients with Advanced or Metastatic NSCLC (SPIRIT II Trial) A randomized, double-blind, placebo controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1 Comparison of BEACOPP and ABVD chemotherapy in intermediate stage Hodgkin's lymphoma: Results of the fourth interim analysis of the HD11 trial of the GHSG E2197: Phase III AT (doxorubicin/docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Cancada Clinical Trials Group (NCIC-CTG) First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable of unfavorable early stage Hodgkin's lymphoma (HL) Gene expression profiles predict pathologic complete response to preoperative chemotherapy with gemcitabine, epirubicin, and docetaxel in primary breast cancer. HD10: Investigating reduction of combined modality treatment intensity in early stage Hodgkin's Lymphoma. Interim analysis of a randomized trial of the German Hodgkin's Study Group (GHSG) High-dose bevacizumab improved survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200 Long-term survival results of a randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients with advanced malignant melanoma Molecular Analysis of the IDEAL/INTACT trials: EGFR Mutations and Gene Amplification Paclitaxel and gemcitabine vs. carboplatin and gemcitabine. A multicenter, phase III randomized trial in patients with advanced inoperable non-small cell lung cancer (NSCLC) Randomized phase II/III trial of paclitaxel (P) plus carboplatin with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599 Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Statins reduce the incidence of lung cancer: A study of half a million U.S. veterans.